News, features, and commentary about cancer-related issues ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

Prostate Cancer UK is calling for sanitary bins to be put in men's public toilets. The charity believes that men who are ...

Research team at OncoRay identifies MMP11 as a promising biomarker for liquid biopsy in prostate cancer Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In ...

Five-year survival rates are among the lowest of all cancers, at about 25%. But when caught early enough – through annual CT ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

Former President Joe Biden made a rare public appearance at the Friday, March 6, funeral for Jesse Jackson amid his cancer battle. Biden, 83, attended the ceremony for the civil rights activist — who ...

We are continuing to see an increase in the incidence of kidney cancer in younger patients over time. Maintaining kidney health involves basic lifestyle choices: avoiding obesity, not smoking, and ...

Her German shepherd saved her life by detecting cancer in its earliest stage–and now an E-nose can detect tumors with AI chemical training.

PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...